145 related articles for article (PubMed ID: 36536927)
1. Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
Schechter BA; Urbieta M; Bacharach J; Toyos M; Smyth-Medina R; Mitchell B; Luchs JI
Clin Ophthalmol; 2022; 16():4145-4151. PubMed ID: 36536927
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
3. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
Tauber J; Schechter BA; Bacharach J; Toyos MM; Smyth-Medina R; Weiss SL; Luchs JI
Clin Ophthalmol; 2018; 12():1921-1929. PubMed ID: 30323548
[TBL] [Abstract][Full Text] [Related]
4. The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Toyos M; Gupta PK; Mitchell B; Karpecki P
Curr Eye Res; 2022 Feb; 47(2):220-224. PubMed ID: 34459350
[TBL] [Abstract][Full Text] [Related]
5. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.
Smyth-Medina R; Johnston J; Devries DK; Jasper A; Kannarr SR; Schechter BA; Shen Lee B; Varghese G; Ogundele A; Darby CH; Karpecki P; Luchs J
J Ocul Pharmacol Ther; 2019 Sep; 35(7):388-394. PubMed ID: 31373837
[No Abstract] [Full Text] [Related]
6. Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study.
Sheppard J; Kannarr S; Luchs J; Malhotra R; Justice A; Ogundele A; Darby C; Bacharach J
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S14-S19. PubMed ID: 31361655
[TBL] [Abstract][Full Text] [Related]
7. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Malhotra R; Devries DK; Luchs J; Kabat A; Schechter BA; Shen Lee B; Shettle L; Smyth-Medina R; Ogundele A; Darby C; Bacharach J; Karpecki P
Cornea; 2019 Oct; 38(10):1259-1265. PubMed ID: 31306284
[TBL] [Abstract][Full Text] [Related]
8. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial.
Pinto-Fraga J; López-Miguel A; González-García MJ; Fernández I; López-de-la-Rosa A; Enríquez-de-Salamanca A; Stern ME; Calonge M
Ophthalmology; 2016 Jan; 123(1):141-53. PubMed ID: 26520171
[TBL] [Abstract][Full Text] [Related]
9. The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye.
Hovanesian JA; Keyser A; Berdy G; Sorensen R
Clin Ophthalmol; 2022; 16():3841-3849. PubMed ID: 36438591
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.
Sheppard J; Bergmann M; Schechter BA; Luchs J; Ogundele A; Karpecki P
Clin Ophthalmol; 2021; 15():129-140. PubMed ID: 33469259
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
[TBL] [Abstract][Full Text] [Related]
13. Topical cyclosporine A therapy for dry eye syndrome.
de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
[TBL] [Abstract][Full Text] [Related]
14. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1).
Wirta DL; Senchyna M; Lewis AE; Evans DG; McLaurin EB; Ousler GW; Hollander DA
Ocul Surf; 2022 Oct; 26():166-173. PubMed ID: 35970431
[TBL] [Abstract][Full Text] [Related]
15. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
16. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease.
Baratta RO; Schlumpf E; Del Buono BJ; DeLorey S; Ousler G; Calkins DJ
Ophthalmol Sci; 2024; 4(3):100451. PubMed ID: 38317866
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
19. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
20. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye.
Stonecipher KG; Torkildsen GL; Ousler GW; Morris S; Villanueva L; Hollander DA
Clin Ophthalmol; 2016; 10():887-95. PubMed ID: 27257373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
